Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 8:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 101 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: PRG Clear all
Completed Phase 4 Interventional Results available

Cyclical Neuroactive Steroid Changes, Arousal, and Proximal Suicide Risk: An Experimental Approach

NCT04112368
View directory record Official record
Conditions
Suicidal Ideation
Interventions
Estradiol Transdermal Patch 0.1 mg/24 hrs, Oral Micronized Progesterone 200mg, Inactive Clear Patch, Placebo capsule
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Oct 21, 2026, 8:59 PM EDT
Recruiting Phase 2 Interventional

Role of Estrogen on Skeletal Outcomes in FHA

NCT07010146
View directory record Official record
Conditions
Bone Strength, Bone Density, FHA (Functional Hypothalamic Amenorrhea)
Interventions
transdermal 17β-E2 with cyclic progestin, oral 17β-E2 with cyclic progestin, transdermal EE+LNG
Drug
Lead sponsor
University of Virginia
Other
Eligibility
14 Years to 30 Years · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
2
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 21, 2026, 8:59 PM EDT
Completed No phase listed Observational

Endometrial Effects of Metformin Action in Women With Polycystic Ovarian Syndrome (PCOS)

NCT01070160
View directory record Official record
Conditions
Polycystic Ovarian Syndrome
Interventions
Endometrin (progesterone 100mg vaginal inserts), Metformin
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 42 Years · Female only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 30, 2020 · Synced Oct 21, 2026, 8:59 PM EDT
Withdrawn Not applicable Interventional

Vaginal Progesterone as a Treatment for Women Active Preterm Labor

NCT01206998
View directory record Official record
Conditions
Labor, Premature
Interventions
Vaginal progesterone gel, Placebo vaginal gel
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 1, 2012 · Synced Oct 21, 2026, 8:59 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Acute Effects of Progesterone on LH Pulses During the Follicular Phase (CRM006)

NCT01602679
View directory record Official record
Conditions
Female Reproductive Physiology
Interventions
oral micronized progesterone suspension, Placebo
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 30 Years · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 16, 2018 · Synced Oct 21, 2026, 8:59 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of Progesterone in Pregnancy-2

NCT04753957
View directory record Official record
Conditions
Pregnancy Related
Interventions
micronized Progesterone
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
16 Years to 55 Years · Female only
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 26, 2022 · Synced Oct 21, 2026, 8:59 PM EDT
Completed Phase 2 Interventional

Progesterone Treatment in Female Smokers - 12

NCT00000295
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
Micronized Progesterone
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Years to 45 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 21, 2026, 8:59 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Kronos Early Estrogen Prevention Study (KEEPS)

NCT00154180
View directory record Official record
Conditions
Menopause, Arteriosclerosis
Interventions
Conjugated equine estrogens 0.45 mg/day, Transdermal estradiol, 50 mcg/day, Micronized progesterone, 200 mg/day x 12 d/month, CEE , progesterone, estradiol patch or placebo for each, CEE, progesterone, transdermal patch or the placebo
Drug
Lead sponsor
Kronos Longevity Research Institute
Other
Eligibility
42 Years to 58 Years · Female only
Enrollment
728 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2012
U.S. locations
9
States / cities
Phoenix, Arizona • San Francisco, California • New Haven, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2009 · Synced Oct 21, 2026, 8:59 PM EDT
Recruiting Phase 2 Interventional

Progestins for the Treatment of Endometrial Cancer or Precancers of the Uterus Before Surgery, The Pro-Window Trial

NCT07436793
View directory record Official record
Conditions
Endometrial Endometrioid Adenocarcinoma, Endometrial Hyperplasia
Interventions
Biopsy Procedure, Curettage Procedure, Hysterectomy, Megestrol Acetate, Progesterone Only Hormone Replacement Therapy
Procedure · Drug
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
18 Years and older · Female only
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
4
States / cities
Iowa City, Iowa • Albuquerque, New Mexico • Salt Lake City, Utah + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 21, 2026, 8:59 PM EDT
Completed Phase 2 Interventional

A Trial to Evaluate DR-2021 in Women With Secondary Amenorrhea

NCT00196391
View directory record Official record
Conditions
Amenorrhea
Interventions
DR-2021a, DR-2021b, DR-2021c, DR-2021d, DR-2021e, Placebo
Drug · Other
Lead sponsor
Duramed Research
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
27
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2014 · Synced Oct 21, 2026, 8:59 PM EDT
Completed Phase 3 Interventional Results available

Oral Progesterone for Prevention of Preterm Birth

NCT01180296
View directory record Official record
Conditions
Preterm Birth
Interventions
oral micronized progesterone, Identical Placebo tablet
Drug
Lead sponsor
Fetal Medicine Foundation
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 18, 2019 · Synced Oct 21, 2026, 8:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Progesterone Amplifies Estrogen-stimulated Growth Hormone Secretion in Older Women

NCT02272647
View directory record Official record
Conditions
Healthy
Interventions
IM Saline Placebo (0.25 ml), IM Estradiol valerate (2.5 mg), IM Saline Placebo (0.5 ml), IM Estradiol valerate (5.0 mg), Oral Micronized Progesterone, Oral Placebo, Ghrelin (0.3 ug/kg), Medroxyprogesterone - Acetate
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
50 Years to 80 Years · Female only
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 22, 2018 · Synced Oct 21, 2026, 8:59 PM EDT
Completed Phase 3 Interventional Results available

A Safety and Efficacy Study of the Combination Estradiol and Progesterone to Treat Vasomotor Symptoms

NCT01942668
View directory record Official record
Conditions
Menopause
Interventions
Estradiol, Progesterone, Placebo
Drug
Lead sponsor
TherapeuticsMD
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
1,845 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
119
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 99 more
Source: ClinicalTrials.gov public record
Updated May 6, 2019 · Synced Oct 21, 2026, 8:59 PM EDT
Completed Not applicable Interventional Results available

Comparison of Transdermal and Oral Estrogens in Adolescent Girls With Ovarian Failure

NCT01023178
View directory record Official record
Conditions
Ovarian Failure, Premature
Interventions
17beta Estradiol, Conjugated estrogens, 17Beta Estradiol - transdermal, Progesterone, micronized
Drug
Lead sponsor
Stanford University
Other
Eligibility
12 Years to 18 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jan 20, 2017 · Synced Oct 21, 2026, 8:59 PM EDT
Active, not recruiting Phase 3 Interventional

Estrogen Administration for the Treatment of NASH in Postmenopausal Women

NCT04833140
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
Estradiol patch, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
45 Years to 70 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 21, 2026, 8:59 PM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

Hormone Replacement Therapy in Adolescents With Premature Ovarian Insufficiency

NCT06851754
View directory record Official record
Conditions
Premature Ovarian Insufficiency
Interventions
Progesterone, Estrogen Patch
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
11 Years to 19 Years · Female only
Enrollment
185 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2031
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 21, 2026, 8:59 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Progesterone for Smoking Relapse Prevention Following Delivery

NCT01972464
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
Progesterone, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 42 Years · Female only
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 17, 2018 · Synced Oct 21, 2026, 8:59 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Vaginal Progesterone to Reduce the Risk of Another Preterm Birth

NCT00086177
View directory record Official record
Conditions
Pregnancy
Interventions
8% progesterone vaginal gel, Placebo Vaginal Gel
Drug
Lead sponsor
Juniper Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
636 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
45
States / cities
Mobile, Alabama • Tucson, Arizona • Colton, California + 39 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2010 · Synced Oct 21, 2026, 8:59 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Vital Signs Blood Pressure Trial

NCT06272318
View directory record Official record
Conditions
Cardiovascular Diseases, Hypertension, Blood Pressure
Interventions
Blood Pressure Cuff, EKG, PPG
Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 64 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 21, 2026, 8:59 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Intravenous Progesterone in Patients With Severe Traumatic Brain Injury

NCT01143064
View directory record Official record
Conditions
Brain Injuries
Interventions
Progesterone, Lipid emulsion without progesterone
Drug
Lead sponsor
BHR Pharma, LLC
Industry
Eligibility
16 Years to 70 Years
Enrollment
1,195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
53
States / cities
Mobile, Alabama • Los Angeles, California • San Diego, California + 48 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2024 · Synced Oct 21, 2026, 8:59 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Uterine Electrical Activity Before and After Progesterone Treatment for Preterm Labor

NCT01406197
View directory record Official record
Conditions
Preterm Labor
Interventions
Experimental: Vaginal progesterone, Experimental: Topical progesterone, Experimental: Intramuscular progesterone
Drug
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
17 Years to 40 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 26, 2022 · Synced Oct 21, 2026, 8:59 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Impact of GABA-Enhancing Agents on Cortical GABA Concentrations Across the Menstrual Cycle in Women

NCT00676026
View directory record Official record
Conditions
Healthy
Interventions
Fluoxetine, Zolpidem, Progesterone
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 1, 2017 · Synced Oct 21, 2026, 8:59 PM EDT
Completed Phase 4 Interventional Results available

Unique Effects of Perimenstrual Estradiol or Progesterone Supplementation on Perimenstrual Suicidality

NCT03498313
View directory record Official record
Conditions
Suicidal Ideation
Interventions
Transdermal Estradiol + Placebo, Oral Micronized Progesterone + Placebo, Placebos
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 14, 2022 · Synced Oct 21, 2026, 8:59 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Regulation of Cervical Mucus Secretion

NCT02969590
View directory record Official record
Conditions
Fertility, Contraception
Interventions
Leuprolide acetate, Estrogen and Progesterone Replacement, Progestin
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
21 Years to 40 Years · Female only
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 18, 2019 · Synced Oct 21, 2026, 8:59 PM EDT